Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/35617
Title: | Global differences and risk factors influencing drug hypersensitivity quality of life: A multicenter, multiethnic study of drug allergy across 3 continents. | Austin Authors: | Copaescu, Ana M;Mak, Hugo W F;Vogrin, Sara;Holmes, Natasha E ;Trubiano, Jason ;Li, Philip H | Affiliation: | Infectious Diseases Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. Centre for Antibiotic Allergy and Research Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. |
Issue Date: | Feb-2025 | Date: | 2024 | Publication information: | The Journal of Allergy and Clinical Immunology. Global 2025-02; 4(1) | Abstract: | Penicillin allergy labels are associated with many adverse outcomes. Fear and restriction of future medication use also have an impact on health-related quality of life (HR-QoL). However, the impact of a drug allergy on HR-QoL and its associated factors remains unknown. We sought to investigate the impact of penicillin allergy labels and compare the factors associated with HR-QoL impairment among patients in an international multicenter, multiethnic cohort. HR-QoL was measured using the 6-item Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) and compared among patients labeled with penicillin allergy, before their allergy evaluation, from 8 adult allergy/immunology clinics across Asia, Australia, and North America. We recruited 643 patients labeled with penicillin allergy (median age, 56 years [interquartile range, 39-67]; male:female ratio, 1:2.2), with 273 (42.5%), 186 (28.9%), and 184 (28.6%) from Asia, North America, and Australia, respectively. The median DrHy-Q score was 8.3 (interquartile range, 0.0-29.2). All patients underwent penicillin allergy evaluation, and 96% (617 of 643) were delabeled following negative provocation test results. Female patients (8.3 vs 4.2; P = .003), those with other concomitant antimicrobial allergy labels (20.8 vs 4.2; P = .004), and patients from Asia (33.3 vs 4.2 [North America] vs 0 [Australia]; P < .001) had significantly higher DrHy-Q scores, reflecting a reduced HR-QoL. Ethnicity as well as other allergy variables were not significant in the multivariate analysis. Regional differences, ethnicity, and other risk factors influence HR-QoL impairment among patients labeled with penicillin allergy. Future studies are needed to understand the contributions of regional sociodemographic factors and identify interventions to improve HR-QoL. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/35617 | DOI: | 10.1016/j.jacig.2024.100354 | ORCID: | Journal: | The Journal of Allergy and Clinical Immunology. Global | Start page: | 100354 | PubMed URL: | 39624181 | ISSN: | 2772-8293 | Type: | Journal Article | Subjects: | Drug allergy delabeling health-related quality of life (HR-QoL) penicillin quality of life |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.